|
Efficacy and tolerance of carboplatin-cetuximab in patients with metastatic or recurrent head and neck squamous cell carcinoma unfit for extreme regimen. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - CellProthera; HalioDx; Janssen-Cilag; OSE Immunotherapeutics; Pfizer |
Travel, Accommodations, Expenses - MSD |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD |
|
|
No Relationships to Disclose |